Protein regulator of cytokinesis 1 overexpression predicts biochemical recurrence in men with prostate cancer |
| |
| Institution: | 1. Department of Urology, Huadu District People’s Hospital, Southern Medical University, Guangzhou 510800, China;2. Guangdong Provincial Institute of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China;3. Department of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People’s Hospital, Guangzhou Medical University, Guangzhou 510180, China;4. School of Marine Sciences, Sun Yat-sen University, Guangzhou 510275,China;5. Urology Key Laboratory of Guangdong Province, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510230, China;1. Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA;2. Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA;3. Cancer Outcomes and Public Policy Effectiveness Research Center, Yale University, New Haven, CT, USA;4. Division of Health Care Policy & Research, Mayo Clinic, Rochester, MN, USA;5. FlatIron Health, New York, NY, USA;6. Department of Medicine, Mayo Clinic, Rochester, MN, USA;7. Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA;8. Department of Radiation Oncology, Yale University, New Haven, CT, USA;9. Department of Urology, Louis Stokes VA Medical Center, Cleveland, OH, USA;10. Glickman Urological and Nephrology Institute, Cleveland Clinic, Cleveland, OH, USA;11. Department of Medicine, Yale University, New Haven, CT, USA;1. Laboratory of Experimental Medicine (ULB Unit 222), University Hospital Center, Charleroi, Belgium;2. Laboratory of Molecular Biology of the Gene, Department of Molecular Biology, Free University of Brussels (ULB), Gosselies, Belgium;3. Inserm, CHU Lille, Biochemistry and Molecular Biology, CBP and University Lille, CHRU Lille, EA 7364, RADEME - Maladies Rares du Développement et du Métabolisme: Du Phénotype au Génotype et à la Fonction, France;1. Department of Heavy Ion Radiation Medicine, Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou 730000, China;2. Key Laboratory of Heavy Ion Radiation Biology and Medicine of Chinese Academy of Sciences, Lanzhou 730000, China;3. Key Laboratory of Heavy Ion Radiation Medicine of Gansu Province, Lanzhou 730000, China;4. University of Chinese Academy of Sciences, Beijing 100049, China;5. College of Veterinary Medicine, Gansu Agricultural University, Lanzhou 730070, China;6. Department of Radiotherapy, Gansu Provincial Hospital, Lanzhou 730000, China;1. Department of Clinical Laboratory, Affiliated Provincial Hospital of Anhui Medical University, Hefei, Anhui, China;2. Center of Reproductive Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China;3. Department of Clinical Laboratory, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China;4. Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, First Affiliated Hospital of University of Science and Technology of China, School of Life Sciences, University of Science and Technology of China, Hefei, Anhui, China;1. Department of Biomarker for Early Detection of Cancer, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan;2. Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo, 104-0045, Japan;3. Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, 104-0045, Japan;4. Japan Agency for Medical Research and Development: AMED-CREST, AMED, Tokyo, 100-0004, Japan |
| |
| Abstract: | BackgroundProtein regulator of cytokinesis 1 (PRC1) has been reported to be implicated into the completion of cytokinesis and is dys-regulated in a cancer-specific manner. However, it roles in human prostate cancer (PCa) remain unclear. In the current study, we aimed to investigate the expression pattern of PRC1 and its clinical significance in this malignancy.Materials and methodsPRC1 protein expression in human PCa and non-cancerous prostate tissues was detected by immunohistochemistry, which was validated by microarray-based Taylor data at mRNA level. Then, the associations of PRC1 expression with clinicopathological features and clinical outcome of PCa patients were statistically analyzed.ResultsPRC1 expression in PCa tissues, at both mRNA and protein levels, were significantly higher than those in non-cancerous prostate tissues. In addition, the PCa patients with PRC1 overexpression more frequently had high Gleason score, advanced pathological stage, positive metastasis, short overall survival time and positive PSA failure than those with low Gleason score, early pathological stage, negative metastasis, long overall survival time and negative PSA failure (all P < 0.05). Moreover, PRC1 expression was identified as an unfavorable prognostic factor of biochemical recurrence-free survival in PCa patients (P < 0.001).ConclusionThese findings suggest that the aberrant expression of PRC1 may predict biochemical recurrence in men with PCa highlighting its potential as a prognostic marker of this malignancy. |
| |
| Keywords: | Prostate cancer Protein regulator of cytokinesis 1 Biochemical recurrence-free survival |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
